Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 3/20 | 0.66 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.61 |
| ▸ | PRKACG | P22612 | 1/20 | 0.61 |
| ▸ | PRKACB | P22694 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30316415 | 1.00 | CYP3A4 (0.67) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL3485985 | 1.00 | CYP3A4 (0.67) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL7258957 | 0.90 | HSPA8 (0.66) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL7258948 | 0.90 | HSPA8 (0.66) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL13835110 | 0.90 | GAPDH (0.70) | HSPA8SLC28A2HSPA5PDE4APDE4B | |
| SCHEMBL13835106 | 0.90 | GAPDH (0.70) | HSPA8SLC28A2HSPA5PDE4APDE4B | |
| SCHEMBL5328057 | 0.89 | RAPGEF3 (0.61) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL30237368 | 0.89 | RAPGEF3 (0.61) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL5328067 | 0.89 | RAPGEF3 (0.61) | CYP3A4MAPTHSPA8SLC28A2HSPA5 | |
| SCHEMBL13834974 | 0.88 | SLC28A2 (0.68) | HSPA8SLC28A2HSPA5PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149554-A2 | METHODS FOR RESTORING NEURAL FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-12-27 | — | — | WO | claimed |
| US-6322784-B1 | GLUCOCORTICOID, A COMPOUND WHICH STIMULATES CAMP PRODUCTION AND COMPOUND WHICH UPREGULATES PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR .GAMMA. EXPRESSION | OSIRIS THERAPEUTICS, INC. | 2001-11-27 | — | — | US | claimed |
| US-20230129380-A1 | Method for Estimating Molecular Complexity | CHEMIFY LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| EP-3486314-B1 | PLACENTAL STEM CELL POPULATIONS | CELULARITY INC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11000554-B2 | Postpartum cells derived from placental tissue, and methods of making and using the same | DePuy Synthes Products, Inc. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20190262406-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS | Celularity, Inc. (US) | 2019-08-29 | — | — | US | disclosed |
| US-10383897-B2 | Placental stem cell populations | Celularity, Inc. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383898-B2 | Postpartum cells derived from placental tissue, and methods of making and using the same | DePuy Synthes Products, Inc. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2019156200-A1 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO INTESTINAL EPITHELIAL CELLS | 公立大学法人名古屋市立大学 | 2019-08-15 | — | — | WO | disclosed |
| US-20190192577-A1 | POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF MAKING AND USING THE SAME | DePuy Synthes Products, Inc. (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3486314-A2 | PLACENTAL STEM CELL POPULATIONS | Celularity, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20040171146-A1 | Adipose-derived stem cells and lattices | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-09-02 | — | — | US | disclosed |
| US-6777231-B1 | A LIPO-DERIVED STEM CELL SUBSTANTIALLY FREE OF ADIPOCYTES AND RED BLOOD CELLS AND CLONAL POPULATIONS OF CONNECTIVE TISSUE STEM CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-08-17 | — | — | US | disclosed |
| US-6709864-B1 | COMPOSITION COMPRISING ISOLATED HUMAN MESENCHYMAL STEM CELLS IN BIOCOMPATIBLE MATRIX WHICH SUPPORTS DIFFERENTIATION AND MATURATION OF STEM CELLS INTO ADIPOCYTES | OSIRIS THERAPEUTICS, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20020076400-A1 | Adipose-derived stem cells and lattices | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-06-20 | — | — | US | disclosed |
| US-6372500-B1 | FOR TRANSFECTION OF EPITHELIAL TISSUE WITH THE CASSETTES IN THERAPY OF CYSTIC FIBROSIS, EMPHYSEMA, CANCERS OF EPITHELIAL ORIGIN ARISING IN THE LUNG OR OTHER ORGANS | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2002-04-16 | — | — | US | disclosed |
| US-6322784-B1 | GLUCOCORTICOID, A COMPOUND WHICH STIMULATES CAMP PRODUCTION AND COMPOUND WHICH UPREGULATES PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR .GAMMA. EXPRESSION | OSIRIS THERAPEUTICS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1080186-A2 | METHOD FOR ALTERING THE ACTIVITY OF PROTEINS OF THE PKA SIGNALING PATHWAY | Lauras AS (NO) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999062315-A2 | METHOD FOR ALTERING THE ACTIVITY OF PROTEINS OF THE PKA SIGNALING PATHWAY | LAURAS AS (NO) | 1999-12-02 | — | — | WO | disclosed |
| WO-1998051807-A1 | EPISOMAL EXPRESSION CASSETTES FOR GENE THERAPY | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383897-B2 | Placental stem cell populations | PGF, ALPP, PROX1 | CYP3A4 4782/4885MAPT 4746/4885HSPA8 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.